Irina Alafuzoff

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5386694/publications.pdf

Version: 2024-02-01

106 papers 12,354 citations

39 h-index 103 g-index

110 all docs

110 docs citations

110 times ranked

13690 citing authors

#	Article	IF	CITATIONS
1	Gastrointestinal Biopsy Obtained During Cancer Screening, a Biological Marker for α-Synucleinopathy?. Journal of Neuropathology and Experimental Neurology, 2022, 81, 356-362.	1.7	1
2	Accumulation of alpha-synuclein within the liver, potential role in the clearance of brain pathology associated with Parkinson's disease. Acta Neuropathologica Communications, 2021, 9, 46.	5.2	14
3	In vivo Characterization of Biochemical Variants of Amyloid-β in Subjects with Idiopathic Normal Pressure Hydrocephalus and Alzheimer's Disease Neuropathological Change. Journal of Alzheimer's Disease, 2021, 80, 1003-1012.	2.6	3
4	The <i>Uppsala APP</i> deletion causes early onset autosomal dominant Alzheimer's disease by altering APP processing and increasing amyloid β fibril formation. Science Translational Medicine, 2021, 13, .	12.4	23
5	Mixed Brain Pathology Is the Most Common Cause of Cognitive Impairment in the Elderly. Journal of Alzheimer's Disease, 2020, 78, 453-465.	2.6	10
6	Modeling SHH-driven medulloblastoma with patient iPS cell-derived neural stem cells. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 20127-20138.	7.1	23
7	Detection of Changes in Immunohistochemical Stains Caused by Postmortem Delay and Fixation Time. Applied Immunohistochemistry and Molecular Morphology, 2019, 27, 238-245.	1.2	15
8	Expression of CMV protein pp65 in cutaneous malignant melanoma. PLoS ONE, 2019, 14, e0223854.	2.5	1
9	Cause of death and significant disease found at autopsy. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 475, 781-788.	2.8	17
10	Predicting Development of Alzheimer's Disease in Patients with Shunted Idiopathic Normal Pressure Hydrocephalus. Journal of Alzheimer's Disease, 2019, 71, 1233-1243.	2.6	28
11	[11C]PIB PET Is Associated with the Brain Biopsy Amyloid- \hat{l}^2 Load in Subjects Examined for Normal Pressure Hydrocephalus. Journal of Alzheimer's Disease, 2019, 67, 1343-1351.	2.6	13
12	Characteristics of the tissue section that influence the staining outcome in immunohistochemistry. Histochemistry and Cell Biology, 2019, 151, 91-96.	1.7	29
13	Alzheimer's disease neuropathological change and loss of matrix/neuropil in patients with idiopathic Normal Pressure Hydrocephalus, a model of Alzheimer's disease. Acta Neuropathologica Communications, 2019, 7, 98.	5.2	15
14	Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain, 2019, 142, 1503-1527.	7.6	873
15	F2â€04â€01: NEUROPATHOLOGY OF VCID: A CLASSICAL LANDSCAPE. Alzheimer's and Dementia, 2019, 15, P521	.0.8	О
16	Progression of Alzheimer's Disease-Related Pathology and Cell Counts in a Patient with Idiopathic Normal Pressure Hydrocephalus. Journal of Alzheimer's Disease, 2018, 61, 1451-1462.	2.6	8
17	Incidence, Comorbidities, and Mortality in Idiopathic Normal PressureÂHydrocephalus. World Neurosurgery, 2018, 112, e624-e631.	1.3	37
18	Brain tissue A $\hat{1}^2$ 42 levels are linked to shunt response in idiopathic normal pressure hydrocephalus. Journal of Neurosurgery, 2018, 130, 121-129.	1.6	25

#	Article	IF	Citations
19	Alpha-synucleinopathies. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 145, 339-353.	1.8	50
20	Slowly progressive dementia caused by MAPT R406W mutations: longitudinal report on a new kindred and systematic review. Alzheimer's Research and Therapy, 2018, 10, 2.	6.2	25
21	Epilepsy in neuropathologically verified Alzheimer's disease. Seizure: the Journal of the British Epilepsy Association, 2018, 58, 9-12.	2.0	17
22	U-CAN: a prospective longitudinal collection of biomaterials and clinical information from adult cancer patients in Sweden. Acta Oncol \tilde{A}^3 gica, 2018, 57, 187-194.	1.8	52
23	The value of magnetic resonance spectroscopy as a supplement to MRI of the brain in a clinical setting. PLoS ONE, 2018, 13, e0207336.	2.5	11
24	Techniques in neuropathology. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 145, 3-7.	1.8	2
25	Comorbidities. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 145, 573-577.	1.8	4
26	Minimal neuropathologic diagnosis for brain banking in the normal middle-aged and aged brain and in neurodegenerative disorders. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 150, 131-141.	1.8	8
27	Glioblastoma Cell Malignancy and Drug Sensitivity Are Affected by the Cell of Origin. Cell Reports, 2017, 18, 977-990.	6.4	46
28	Multisite Assessment of Aging-Related Tau Astrogliopathy (ARTAG). Journal of Neuropathology and Experimental Neurology, 2017, 76, 605-619.	1.7	38
29	Mouse Models of Pediatric Supratentorial High-grade Glioma Reveal How Cell-of-Origin Influences Tumor Development and Phenotype. Cancer Research, 2017, 77, 802-812.	0.9	15
30	Transactive DNA Binding Protein 43 Rather Than Other Misfolded Proteins in the Brain is Associated with Islet Amyloid Polypeptide in Pancreas in Aged Subjects with Diabetes Mellitus. Journal of Alzheimer's Disease, 2017, 59, 43-56.	2.6	7
31	Mast Cell Infiltration in Human Brain Metastases Modulates the Microenvironment and Contributes to the Metastatic Potential. Frontiers in Oncology, 2017, 7, 115.	2.8	10
32	Prognostic markers for survival in patients with oligodendroglial tumors; a single-institution review of 214 cases. PLoS ONE, 2017, 12, e0188419.	2.5	11
33	Diffusion kurtosis imaging of gliomas grades II and III - a study of perilesional tumor infiltration, tumor grades and subtypes at clinical presentation. Radiology and Oncology, 2017, 51, 121-129.	1.7	37
34	Preoperative Quantitative MR Tractography Compared with Visual Tract Evaluation in Patients with Neuropathologically Confirmed Gliomas Grades II and III: A Prospective Cohort Study. Radiology Research and Practice, 2016, 2016, 1-15.	1.3	6
35	Beer Drinking Associates with Lower Burden of Amyloid Beta Aggregation in the Brain: Helsinki Sudden Death Series. Alcoholism: Clinical and Experimental Research, 2016, 40, 1473-1478.	2.4	18
36	Using the Disease State Fingerprint Tool for Differential Diagnosis of Frontotemporal Dementia and Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders Extra, 2016, 6, 313-329.	1.3	12

3

#	Article	IF	Citations
37	Mechanical reperfusion with leucocyte-filtered blood does not prevent injury following global cerebral ischaemia. European Journal of Cardio-thoracic Surgery, 2016, 51, ezw367.	1.4	1
38	Human Traumatic Brain Injury Results in Oligodendrocyte Death and Increases the Number of Oligodendrocyte Progenitor Cells. Journal of Neuropathology and Experimental Neurology, 2016, 75, 503-515.	1.7	51
39	High Risk of Dementia in Ventricular Enlargement with Normal Pressure Hydrocephalus Related Symptoms1. Journal of Alzheimer's Disease, 2016, 52, 497-507.	2.6	36
40	Effects of Alzheimer's Disease-Associated Risk Loci on Amyloid-β Accumulation in the Brain of Idiopathic Normal Pressure Hydrocephalus Patients. Journal of Alzheimer's Disease, 2016, 55, 995-1003.	2.6	6
41	Targeting coagulation factor XII as a novel therapeutic option in brain trauma. Annals of Neurology, 2016, 79, 970-982.	5.3	28
42	Multimodal analysis to predict shunt surgery outcome of 284 patients with suspected idiopathic normal pressure hydrocephalus. Acta Neurochirurgica, 2016, 158, 2311-2319.	1.7	21
43	Post-mortem assessment in vascular dementia: advances and aspirations. BMC Medicine, 2016, 14, 129.	5.5	99
44	Atypical Huntington's disease with the clinical presentation of behavioural variant of frontotemporal dementia. Journal of Neural Transmission, 2016, 123, 1423-1433.	2.8	2
45	Aging-related tau astrogliopathy (ARTAG): harmonized evaluation strategy. Acta Neuropathologica, 2016, 131, 87-102.	7.7	380
46	Altered Proteins in the Aging Brain. Journal of Neuropathology and Experimental Neurology, 2016, 75, 316-325.	1.7	153
47	Extension of diffuse low-grade gliomas beyond radiological borders as shown by the coregistration of histopathological and magnetic resonance imaging data. Journal of Neurosurgery, 2016, 125, 1155-1166.	1.6	58
48	Oncogene-Induced Senescence in Pituitary Adenomasâ€"an Immunohistochemical Study. Endocrine Pathology, 2016, 27, 1-11.	9.0	16
49	Pleiotrophin enhances PDGFB-induced gliomagenesis through increased proliferation of neural progenitor cells. Oncotarget, 2016, 7, 80382-80390.	1.8	15
50	The Expression of Transthyretin and Amyloid- \hat{l}^2 Protein Precursor is Altered in the Brain of Idiopathic Normal Pressure Hydrocephalus Patients. Journal of Alzheimer's Disease, 2015, 48, 959-968.	2.6	19
51	Amyloid-Î ² and Tau Dynamics in Human Brain Interstitial Fluid in Patients with Suspected Normal Pressure Hydrocephalus. Journal of Alzheimer's Disease, 2015, 46, 261-269.	2.6	39
52	To Stage Alzheimer's Disease Related Neurodegeneration Using one Section ofÂHippocampus. Journal of Alzheimer's Disease, 2015, 48, 597-601.	2.6	1
53	The Human Glioblastoma Cell Culture Resource: Validated Cell Models Representing All Molecular Subtypes. EBioMedicine, 2015, 2, 1351-1363.	6.1	228
54	Correlations Between Mini-Mental State Examination Score, Cerebrospinal Fluid Biomarkers, and Pathology Observed in Brain Biopsies of Patients With Normal-Pressure Hydrocephalus. Journal of Neuropathology and Experimental Neurology, 2015, 74, 470-479.	1.7	48

#	Article	IF	Citations
55	Neuropathological assessments of the pathology in frontotemporal lobar degeneration with TDP43-positive inclusions: an inter-laboratory study by the BrainNet Europe consortium. Journal of Neural Transmission, 2015, 122, 957-972.	2.8	25
56	Transcriptomics and mechanistic elucidation of Alzheimer's disease risk genes in the brain and inÂvitro models. Neurobiology of Aging, 2015, 36, 1221.e15-1221.e28.	3.1	55
57	Interleukin-18 alters protein expressions of neurodegenerative diseases-linked proteins in human SH-SY5Y neuron-like cells. Frontiers in Cellular Neuroscience, 2014, 8, 214.	3.7	22
58	Subtyping of gliomas of various $\langle scp \rangle WHO \langle scp \rangle$ grades by the application of immunohistochemistry. Histopathology, 2014, 64, 365-379.	2.9	56
59	Cerebrospinal Fluid Biomarker and Brain Biopsy Findings in Idiopathic Normal Pressure Hydrocephalus. PLoS ONE, 2014, 9, e91974.	2.5	91
60	Alzheimer's diseaseâ€related plaques in nondemented subjects. Alzheimer's and Dementia, 2014, 10, 522-529.	0.8	8
61	Staged pathology in Parkinson's disease. Parkinsonism and Related Disorders, 2014, 20, S57-S61.	2.2	11
62	Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathologica, 2014, 128, 755-766.	7.7	1,060
63	Long-term memory performance after surgical treatment of unilateral temporal lobe epilepsy (TLE). Epilepsy Research, 2014, 108, 1228-1237.	1.6	14
64	Increased \hat{I}^3 -Secretase Activity in Idiopathic Normal Pressure Hydrocephalus Patients with \hat{I}^2 -Amyloid Pathology. PLoS ONE, 2014, 9, e93717.	2.5	12
65	Human Cytomegalovirus Tegument Protein pp65 Is Detected in All Intra- and Extra-Axial Brain Tumours Independent of the Tumour Type or Grade. PLoS ONE, 2014, 9, e108861.	2.5	37
66	Synucleinopathies., 2014, , 149-175.		0
67	Poor Cognitive Outcome in Shunt-Responsive Idiopathic Normal Pressure Hydrocephalus. Neurosurgery, 2013, 72, 1-8.	1.1	129
68	APOE4 predicts amyloid- \hat{l}^2 in cortical brain biopsy but not idiopathic normal pressure hydrocephalus. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 1119-1124.	1.9	23
69	Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature. Journal of Neuropathology and Experimental Neurology, 2012, 71, 362-381.	1.7	1,599
70	O1-01-01: Cerebrospinal fluid biomarkers for Alzheimer's disease are associated with neuropathology in cortical brain biopsy., 2012, 8, P83-P84.		0
71	The need to unify neuropathological assessments of vascular alterations in the ageing brain. Experimental Gerontology, 2012, 47, 825-833.	2.8	57
72	An antibody with high reactivity for disease-associated \hat{l}_{\pm} -synuclein reveals extensive brain pathology. Acta Neuropathologica, 2012, 124, 37-50.	7.7	133

#	Article	IF	CITATIONS
73	Unusual clinical presentation and neuropathology in two subjects with fusedâ€in sarcoma (FUS) positive inclusions. Neuropathology, 2012, 32, 60-68.	1.2	1
74	Novel amplifications in pediatric medulloblastoma identified by genome-wide copy number profiling. Journal of Neuro-Oncology, 2012, 107, 37-49.	2.9	3
75	Hyperphosphorylated tau in young and middle-aged subjects. Acta Neuropathologica, 2012, 123, 97-104.	7.7	82
76	Alzheimer's Disease-Related Lesions. Journal of Alzheimer's Disease, 2012, 33, S173-S179.	2.6	4
77	New lexicon and criteria for the diagnosis of Alzheimer's disease. Lancet Neurology, The, 2011, 10, 298-299.	10.2	26
78	TAR-DNA binding protein-43 and alterations in the hippocampus. Journal of Neural Transmission, 2011, 118, 683-689.	2.8	24
79	Distribution and Pattern of Pathology in Subjects with Familial or Sporadic Late-Onset Cerebellar Ataxia as Assessed by p62/Sequestosome Immunohistochemistry. Cerebellum, 2011, 10, 720-731.	2.5	11
80	The Effect of Prolonged Fixation Time on Immunohistochemical Staining of Common Neurodegenerative Disease Markers. Journal of Neuropathology and Experimental Neurology, 2010, 69, 40-52.	1.7	49
81	Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathologica, 2010, 119, 1-4.	7.7	854
82	Amyloid and tau proteins in cortical brain biopsy and Alzheimer's disease. Annals of Neurology, 2010, 68, 446-453.	5.3	128
83	Ubiquitinated p62-positive, TDP-43-negative inclusions in cerebellum in frontotemporal lobar degeneration with TAR DNA binding protein 43. Neuropathology, 2010, 30, 197-199.	1.2	18
84	Does protein expression predict recurrence of benign World Health Organization grade I meningioma?. Human Pathology, 2010, 41, 199-207.	2.0	19
85	Assessment of \hat{l}^2 -amyloid deposits in human brain: a study of the BrainNet Europe Consortium. Acta Neuropathologica, 2009, 117, 309-320.	7.7	143
86	Staging/typing of Lewy body related $\hat{l}\pm$ -synuclein pathology: a study of the BrainNet Europe Consortium. Acta Neuropathologica, 2009, 117, 635-652.	7.7	249
87	Applicability of current staging/categorization of \hat{l}_{\pm} -synuclein pathology and their clinical relevance. Acta Neuropathologica, 2008, 115, 399-407.	7.7	294
88	Inter-laboratory comparison of neuropathological assessments of \hat{l}^2 -amyloid protein: a study of the BrainNet Europe consortium. Acta Neuropathologica, 2008, 115, 533-546.	7.7	86
89	Management of a twenty-first century brain bank: experience in the BrainNet Europe consortium. Acta Neuropathologica, 2008, 115, 497-507.	7.7	101
90	Staging of Neurofibrillary Pathology in Alzheimer's Disease: A Study of the BrainNet Europe Consortium. Brain Pathology, 2008, 18, 484-496.	4.1	361

#	Article	IF	Citations
91	Systematic Appraisal Using Immunohistochemistry of Brain Pathology in Aged and Demented Subjects. Dementia and Geriatric Cognitive Disorders, 2008, 25, 423-432.	1.5	23
92	Mixed Brain Pathologies in Dementia: The BrainNet Europe Consortium Experience. Dementia and Geriatric Cognitive Disorders, 2008, 26, 343-350.	1.5	148
93	Assessment of α-Synuclein Pathology: A Study of the BrainNet Europe Consortium. Journal of Neuropathology and Experimental Neurology, 2008, 67, 125-143.	1.7	73
94	Neuropathologic Features of Frontotemporal Lobar Degeneration With Ubiquitin-Positive Inclusions Visualized With Ubiquitin-Binding Protein p62 Immunohistochemistry. Journal of Neuropathology and Experimental Neurology, 2008, 67, 280-298.	1.7	76
95	Interlaboratory Comparison of Assessments of Alzheimer Disease-Related Lesions: A Study of the BrainNet Europe Consortium. Journal of Neuropathology and Experimental Neurology, 2006, 65, 740-757.	1.7	95
96	Human Postmortem Brain Tissue and 2-mm Tissue Microarrays. Applied Immunohistochemistry and Molecular Morphology, 2006, 14, 353-359.	1,2	18
97	Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathologica, 2006, 112, 389-404.	7.7	2,318
98	Postmortem Examination of Vascular Lesions in Cognitive Impairment. Stroke, 2006, 37, 1005-1009.	2.0	82
99	Widespread and abundant αâ€synuclein pathology in a neurologically unimpaired subject. Neuropathology, 2005, 25, 304-314.	1.2	71
100	αâ€Synuclein pathology does not predict extrapyramidal symptoms or dementia. Annals of Neurology, 2005, 57, 82-91.	5.3	287
101	Morphogenesis of Lewy Bodies: Dissimilar Incorporation of $\hat{l}\pm$ -Synuclein, Ubiquitin, and p62. Journal of Neuropathology and Experimental Neurology, 2003, 62, 1241-1253.	1.7	240
102	Ubiquitin-binding protein p62 is present in neuronal and glial inclusions in human tauopathies and synucleinopathies. NeuroReport, 2001, 12, 2085-2090.	1.2	316
103	Lower Counts of Astroglia and Activated Microglia in Patients with Alzheimer's Disease with Regular Use of Non-Steroidal Anti-Inflammatory Drugs. Journal of Alzheimer's Disease, 2000, 2, 37-46.	2.6	41
104	Severity of Cardiovascular Disease, Apolipoprotein E Genotype, and Brain Pathology in Aging and Dementia. Annals of the New York Academy of Sciences, 2000, 903, 244-251.	3.8	39
105	Upregulated expression of Fas and Fas ligand in brain through the spectrum of HIV-1 infection. Acta Neuropathologica, 1999, 98, 355-362.	7.7	23
106	Pitfalls in the quantitative estimation of \hat{l}^2 -amyloid immunoreactivity in human brain tissue. Histochemistry and Cell Biology, 1998, 110, 439-445.	1.7	14